Subjective Cognitive Decline (SCD)

0
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
2 programs
Cog Fun Ageing interventionN/A1 trial
Cog Fun Ageing interventionN/A1 trial
Active Trials
NCT06632145Recruiting30Est. Apr 2025
NCT06816797Recruiting40Est. Aug 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
Jerusalem PharmaceuticalsCog Fun Ageing intervention
Jerusalem PharmaceuticalsCog Fun Ageing intervention

Clinical Trials (2)

Total enrollment: 70 patients across 2 trials

NCT06816797Jerusalem PharmaceuticalsCog Fun Ageing intervention

Testing the Cog-Fun Aging Program for Older Adults With Subjective Cognitive Decline

Start: Nov 2024Est. completion: Aug 202540 patients
N/ARecruiting
NCT06632145Jerusalem PharmaceuticalsCog Fun Ageing intervention

Cog-Fun Ageing Participation-centered, Health Promotion for Older Adults

Start: Apr 2024Est. completion: Apr 202530 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 70 patients
1 companies competing in this space